• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors

    11/4/24 7:30:00 AM ET
    $ATNM
    $AVTX
    $RDHL
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ATNM alert in real time by email

    -       Dr. Almenoff brings more than 25 years of drug development and leadership

    experience to the Actinium Board of Directors  

    -       Dr. Almenoff to join Actinium's Nominating and Corporate Governance Committee

    NEW YORK, Nov. 4, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced the appointment of June Almenoff, M.D., Ph.D. to its Board of Directors. Dr. Almenoff is an accomplished biopharma executive with over 25 years of senior leadership and drug development experience. She currently serves as a Board Director and advisor to numerous biopharma companies. 

    (PRNewsfoto/Actinium Pharmaceuticals, Inc.)

    Andes Seth, Actinium's Chairman and CEO, stated, "Through her career, June has amassed significant experience in translational research, drug development and business development that has resulted in multiple approved products and value creation. Her experience will be invaluable to Actinium and we are delighted to add Dr. Almenoff to the Actinium Board."

    Dr. Almenoff served as President and Chief Medical Officer of Furiex Pharmaceuticals, which was acquired by Actavis plc (now AbbVie) for $1.2B. Furiex developed eluxadoline (Viberzi®), which was approved both in the United States and Europe. She also served as Chief Medical Officer of RedHill Biopharma Ltd (NASDAQ:RDHL) leading a team whose work led to the recognition of Talicia® as a first-line therapy for H. pylori.  Earlier in her career, Dr. Almenoff was at GlaxoSmithKline (GSK) for 12 years, where she held various positions of increasing responsibility. She was a Vice President in the Clinical Safety Organization, chaired a PhRMA-FDA working group, and worked in the area of scientific licensing. She also led the development of pioneering data analytics systems, which have been widely adopted by industry and regulators to minimize clinical risk for pharmaceutical products.

    Dr. Almenoff has strong expertise in translational medicine, clinical development, commercial strategy, and business development across many therapeutic areas, and has led or contributed to numerous regulatory submissions, product approvals and launches. She is a member of the investment advisory board of the Harrington Discovery Institute, a director on the board of Avalo Therapeutics, Inc. (NASDAQ:AVTX) and Tenax Therapeutics (NASDAQ:TENX).

    Dr. Almenoff added, "Targeted radiotherapy has become an important treatment option for patients in multiple oncology indications, which I believe will only continue to expand. I am impressed by Actinium's innovative R&D, clinical development experience and capabilities, as well as its proprietary Actinium-225 manufacturing technology. Collectively, Actinium has the vision and components to become a leading fully integrated specialty radiopharmaceutical company. I am excited to join the Actinium Board and look forward to working to help the company realize its vision and create value for patients and shareholders alike."

    Dr. Almenoff received her B.A. cum laude from Smith College and graduated with Alpha Omega Alpha honors from the M.D.-Ph.D. program at the Icahn (Mt. Sinai) School of Medicine. She completed post-graduate medical training at Stanford University Medical Center and served on the faculty of Duke University School of Medicine. She is an adjunct professor at Duke, a Fellow of the American College of Physicians (FACP) and has authored over 70 publications.

    About Actinium Pharmaceuticals, Inc.

    Actinium develops Antibody Radiation Conjugates ("ARCs") and other targeted radiotherapies intended to meaningfully improve outcomes for people who have failed existing oncology therapies. Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia ("r/r AML"), which Actinium is seeking a potential strategic partner for in the U.S. The company continues to advance its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, Actinium is engaged with the National Cancer Institute ("NCI") under the Cooperative Research and Development Agreement ("CRADA") for development of Actimab-A in AML and other myeloid malignancies. Iomab-ACT, Actinium's next generation conditioning candidate, is being developed with the goal of improving patient access and outcomes for potentially curative cell and gene therapies. In addition, the company's R&D efforts are primarily focused on advancing several preclinical programs for solid tumor indications. Actinium holds more than 235 patents and patent applications including several patents related to the manufacture of the isotope Ac-225 in a cyclotron.

    For more information, please visit: https://www.actiniumpharma.com/

    Forward-Looking Statements

    This press release may contain projections or other "forward-looking statements" within the meaning of the "safe-harbor" provisions of the private securities litigation reform act of 1995 regarding future events or the future financial performance of the Company which the Company undertakes no obligation to update. These statements are based on management's current expectations and are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with preliminary study results varying from final results, estimates of potential markets for drugs under development, clinical trials, actions by the FDA and other governmental agencies, regulatory clearances, responses to regulatory matters, the market demand for and acceptance of Actinium's products and services, performance of clinical research organizations and other risks detailed from time to time in Actinium's filings with the Securities and Exchange Commission (the "SEC"), including without limitation its most recent annual report on form 10-K, subsequent quarterly reports on Forms 10-Q and Forms 8-K, each as amended and supplemented from time to time.

    Investors:

    [email protected] 

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/actinium-pharmaceuticals-appoints-accomplished-biopharma-industry-executive-june-almenoff-md-phd-to-its-board-of-directors-302295025.html

    SOURCE Actinium Pharmaceuticals, Inc.

    Get the next $ATNM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ATNM
    $AVTX
    $RDHL
    $TENX

    CompanyDatePrice TargetRatingAnalyst
    Avalo Therapeutics Inc.
    $AVTX
    3/25/2025$36.00Buy
    Stifel
    Avalo Therapeutics Inc.
    $AVTX
    3/25/2025$23.00Buy
    Jefferies
    Avalo Therapeutics Inc.
    $AVTX
    2/28/2025$48.00Overweight
    Piper Sandler
    Avalo Therapeutics Inc.
    $AVTX
    2/21/2025$18.00Outperform
    Wedbush
    Avalo Therapeutics Inc.
    $AVTX
    12/19/2024$40.00Buy
    BTIG Research
    Tenax Therapeutics Inc.
    $TENX
    10/24/2024$16.00Outperform
    Leerink Partners
    Avalo Therapeutics Inc.
    $AVTX
    10/24/2024Neutral
    H.C. Wainwright
    Tenax Therapeutics Inc.
    $TENX
    10/14/2024$16.00Buy
    Guggenheim
    More analyst ratings

    $ATNM
    $AVTX
    $RDHL
    $TENX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Actinium Announces Enrollment of First Patient in the Iomab-ACT Commercial CAR-T Trial at the University of Texas Southwestern Medical Center

      -       Initial clinical data expected in the second half of 2025 from this first-of-its-kind trial to administer a targeted radiotherapy conditioning agent with a commercial CAR-T therapy -       Iomab-ACT supported by results of NIH funded trial with MSK showing effective lymphodepletion of targeted immune cells resulting in negligible rates of CAR-T toxicities ICANS and CRS and CAR T-cell persistence with a novel CD19 CAR-T therapy -       Iomab-ACT has the potential to increase the addressable market for CAR-T therapies, which generated $4 billion in sales in 2024, by enabling improved access and better patient outcomes compared to current chemotherapy conditioning agents NEW YORK, May 6

      5/6/25 8:45:00 AM ET
      $ATNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • RedHill-Supported Medscape H. Pylori Educational Program to Launch at Major Gastroenterology Congress

      RedHill supports an independent medical education grant that includes a new two-part H. Pylori Continuing Medical Education (CME) program, developed by Medscape aimed at advancing clinical knowledge and improving patient outcomes -- The first part of the program, led by a faculty of William Chey, MD, Vivian Asamoah, MD and Shailja Shah, MD, MPH, will take place May 6 during a major U.S. gastroenterology meeting -- H. pylori is classified by the World Health Organization (WHO) as a Group 1 carcinogen, being the strongest known risk factor for gastric cancer[1] and a major risk factor for peptic ulcer disease[2]. With almost half the global population infected by H. pylori[3], its treatment re

      5/2/25 7:00:00 AM ET
      $RDHL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avalo Therapeutics to Participate in The Citizens Life Sciences Conference

      WAYNE, Pa. and ROCKVILLE, Md., April 30, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that Dr. Garry Neil, Chief Executive Officer of Avalo, will present at the Citizens Life Sciences Conference in New York on Thursday, May 8, 2025, at 3:00 pm ET. Live webcasts and replays, when available, can be found under "News / Events" in the Investors section of the Avalo Therapeutics website at https://ir.avalotx.com. The archived webcast will be available for replay for at least 30 days. About Avalo Therapeutics Avalo Therapeutics is a clinical stage biotechnology company

      4/30/25 7:00:00 AM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATNM
    $AVTX
    $RDHL
    $TENX
    SEC Filings

    See more
    • SEC Form 10-Q filed by Actinium Pharmaceuticals Inc. (Delaware)

      10-Q - Actinium Pharmaceuticals, Inc. (0001388320) (Filer)

      5/9/25 5:27:35 PM ET
      $ATNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Actinium Pharmaceuticals Inc. (Delaware) filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

      8-K - Actinium Pharmaceuticals, Inc. (0001388320) (Filer)

      5/9/25 5:00:08 PM ET
      $ATNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avalo Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Avalo Therapeutics, Inc. (0001534120) (Filer)

      5/8/25 7:02:47 AM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATNM
    $AVTX
    $RDHL
    $TENX
    Financials

    Live finance-specific insights

    See more
    • Actinium Pharmaceuticals Highlights Antibody Radiation Conjugate Program Developments and Reports Financial Results for the Third Quarter 2024

      -  Aligned with FDA on operationally seamless Phase 2/3 trial for Actimab-A + CLAG-M in relapsed/refractory acute myeloid leukemia -  Actimab-A selected for National Cancer Institute's recently opened myeloMATCH precision medicines program for patients with acute myeloid leukemia and myelodysplastic syndromes -  Two Iomab-ACT INDs cleared by FDA: Commercial CAR-T trial at University of Texas Southwestern and sickle cell transplant trial at Columbia University; proof-of-concept safety and efficacy data expected in 2025 -  Actinium seeking U.S. strategic partner for Iomab-B to conduct dose optimization and head-to-head Phase 3 trial based on FDA guidance in adult patients with active relapsed

      11/18/24 8:00:00 AM ET
      $ATNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Actinium Announces Positive Full Data Results From the Pivotal Phase 3 SIERRA Trial in Patients with Active, Relapsed or Refractory Acute Myeloid Leukemia

      -  Iomab-B met the primary endpoint of durable Complete Remission (dCR) of 6-months following initial complete remission after BMT with high statistical significance (p-value of <0.0001), 22% of patients achieved dCR in the Iomab-B arm compared to 0% in the control arm -  In patients achieving 6-month dCR with Iomab-b, 1-year survival of 92% and 2-year survival of 60% was achieved; median overall survival (OS) has not been reached in these patients -  Iomab-B demonstrated significant improvement in Event Free Survival (EFS) with a Hazard Ratio = 0.22, p<0.0001 -  Iomab-B doubled 1-year survival and median overall survival compared to control arm patients who did not crossover -  Iomab-B was

      2/18/23 4:30:00 PM ET
      $ATNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Actinium to Present Full Results from Pivotal Phase 3 Iomab-B SIERRA Trial on Investor Call Following the Late-Breaker Presentation at the 2023 Transplantation & Cellular Therapy Tandem Meetings on Saturday, February 18, 2023

      -  Late-breaker presentation at 5:00 PM EST on Saturday, February 18, 2023, to feature Iomab-B SIERRA Pivotal Trial results -  Investor call at 6:00 PM EST on Saturday, February 18, 2023, to highlight full results from the Phase 3 SIERRA trial NEW YORK, Feb. 14, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE:ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies, today announced its presence at the upcoming Tandem Meetings: Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR) being held February 15 – 19,

      2/14/23 7:30:00 AM ET
      $ATNM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATNM
    $AVTX
    $RDHL
    $TENX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Steinhart Richard I

      4 - Actinium Pharmaceuticals, Inc. (0001388320) (Issuer)

      4/2/25 6:22:33 PM ET
      $ATNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Chell Jeffrey W.

      4 - Actinium Pharmaceuticals, Inc. (0001388320) (Issuer)

      4/2/25 6:22:19 PM ET
      $ATNM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Almenoff June Sherie

      4 - Actinium Pharmaceuticals, Inc. (0001388320) (Issuer)

      4/2/25 6:22:02 PM ET
      $ATNM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATNM
    $AVTX
    $RDHL
    $TENX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Stifel initiated coverage on Avalo Therapeutics with a new price target

      Stifel initiated coverage of Avalo Therapeutics with a rating of Buy and set a new price target of $36.00

      3/25/25 8:26:24 AM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies initiated coverage on Avalo Therapeutics with a new price target

      Jefferies initiated coverage of Avalo Therapeutics with a rating of Buy and set a new price target of $23.00

      3/25/25 8:26:24 AM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on Avalo Therapeutics with a new price target

      Piper Sandler initiated coverage of Avalo Therapeutics with a rating of Overweight and set a new price target of $48.00

      2/28/25 7:19:02 AM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATNM
    $AVTX
    $RDHL
    $TENX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Tenax Therapeutics Inc.

      SC 13G - TENAX THERAPEUTICS, INC. (0000034956) (Subject)

      11/14/24 7:14:21 PM ET
      $TENX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Avalo Therapeutics Inc.

      SC 13G - Avalo Therapeutics, Inc. (0001534120) (Subject)

      11/14/24 6:23:00 PM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Redhill Biopharma Ltd.

      SC 13G/A - RedHill Biopharma Ltd. (0001553846) (Subject)

      11/14/24 12:22:08 PM ET
      $RDHL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATNM
    $AVTX
    $RDHL
    $TENX
    Leadership Updates

    Live Leadership Updates

    See more
    • Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board

      WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, today announced the appointment of Michael Heffernan as Chairman of the Board of Directors ("Board"). Mr. Heffernan will succeed Dr. Garry Neil as Chairman of the Board. Dr. Neil will continue as a Board member and Chief Executive Officer (CEO) of the Company. "We are thrilled to welcome Michael to Avalo's Board of Directors during this pivotal time in our Company's growth," said Dr. Garry Neil, CEO of Avalo Therapeutics. "Michael's extensive experience in building and leading biopharmaceutical companie

      3/26/25 7:00:00 AM ET
      $AVTX
      $BHVN
      $COLL
      $TRVI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avalo Reports 2024 Financial Results and Recent Business Updates

      Topline data from Phase 2 LOTUS Trial of AVTX-009 for the treatment of hidradenitis suppurativa expected in 2026 Appointed Jennifer Riley as Chief Strategy Officer Cash on hand of approximately $135 million as of December 31, 2024 expected to provide runway into at least 2027 WAYNE, Pa. and ROCKVILLE, Md., March 20, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced business updates and year-end financial results for 2024. "2024 was a transformational year for Avalo, and I am proud of the accomplishments the team has made in a short amount of time," said Dr. Garry Neil,

      3/20/25 7:00:00 AM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tenax Therapeutics Appoints Gillian Andor Vice President, Clinical Operations

      CHAPEL HILL, N.C., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX) ("Tenax Therapeutics" or the "Company"), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced the appointment of Gillian Andor, MSc, as Vice President, Clinical Operations. Ms. Andor will lead the Company's expanding Clinical Operations function in support of the ongoing Phase 3 program evaluating oral levosimendan (TNX-103) for the treatment of pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF). "We are

      1/22/25 8:00:00 AM ET
      $TENX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ATNM
    $AVTX
    $RDHL
    $TENX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Almenoff June Sherie bought $12,750 worth of shares (1,000 units at $12.75) (SEC Form 4)

      4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

      11/14/24 5:21:55 PM ET
      $AVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Proehl Gerald T bought 1,666 shares, increasing direct ownership by 166,600% to 1,667 units (SEC Form 4)

      4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)

      8/8/24 7:43:25 PM ET
      $TENX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Davidson Michael H. bought 2,500 shares, increasing direct ownership by 656% to 2,881 units (SEC Form 4)

      4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)

      8/8/24 7:42:23 PM ET
      $TENX
      Biotechnology: Pharmaceutical Preparations
      Health Care